Stay informed about the latest diabetes news and research, including medical discoveries, treatment developments, clinical studies, technology and emerging health insights.
A shift towards a cohesive cardiovascular-kidney-metabolic framework is prompting NHS service redesigns, emphasising early detection, broader treatment strategies, and addressal of health disparities amidst growing recognition of interconnected chronic conditions. Cardiovascular-kidney-metabolic care is emerging as a more realistic way to…
New research suggests that orally administered lithocholic acid may improve glucose regulation by activating specific bile acid receptors, altering gut bacteria, and reducing liver glucose production in a rat model of type 2 diabetes. In a rat study, lithocholic acid…
A study from the UAE suggests that combining aerobic and resistance training may reduce HbA1c levels and alter haemoglobin glycation profiles in adults with type 2 diabetes, highlighting the complex biological effects of exercise on glucose processing. Physical activity may…
Surrozen has received FDA approval to test SZN-8141, a promising bifunctional antibody aimed at tackling diabetic macular edema. Early results are expected in 2027, marking a significant step in retinal disease treatment development. The U.S. Food and Drug Administration has…
VTV Therapeutics has finished enrolling 166 participants in its phase 3 CATT1 study of cadisegliatin, an experimental oral drug aimed at reducing hypoglycaemia and improving glucose control in adults with type 1 diabetes, with topline results expected by mid-2027. vTv…
Rezolute reports that the US Food and Drug Administration has suggested a pre-BLA meeting for ersodetug, following a mixed Phase 3 trial in congenital hyperinsulinism, as the company prepares for potential approval in a high-need rare disease area. Rezolute said…
The American Diabetes Association and the European Association for the Study of Diabetes have revised their joint guidelines, moving away from metformin as the default initial therapy for type 2 diabetes towards personalised treatment options including SGLT2 and GLP-1 therapies,…
A recent study presented in Milan indicates that very low-carbohydrate diets may improve blood sugar control and reduce insulin needs in children with type 1 diabetes without immediate safety concerns, though longer-term research is needed. Very low-carbohydrate diets may help…
A new triple-hormonal drug, retatrutide, demonstrates substantial weight loss and improved blood glucose control in its largest trial to date, signalling potential for a breakthrough in obesity and type 2 diabetes treatment, though regulatory approval is still pending. Retatrutide, an…
Retatrutide, a novel triple-action hormone drug, shows promising results in weight loss and diabetes management, signalling a shift towards more aggressive obesity therapies pending regulatory approval. Retatrutide has emerged as one of the most closely watched experimental obesity medicines because…
Eli Lilly’s novel combination of amylin drug eloralintide with tirzepatide shows significant weight loss and improved blood sugar control in phase 2 trials, posing a challenge to competitors despite concerns over side effects. Eli Lilly has once again widened its…
Boehringer Ingelheim’s experimental weekly injection, survodutide, demonstrates significant weight loss and better blood sugar control in a phase 3 trial, offering a potential new approach to tackling obesity and diabetes, though concerns around tolerability remain. An experimental weekly injection from…
